Man Group plc Acquires New Shares in Celcuity, Inc. $CELC

Man Group plc bought a new stake in Celcuity, Inc. (NASDAQ:CELC) during the 2nd quarter, Holdings Channel reports. The fund bought 28,845 shares of the company’s stock, valued at approximately $3,018,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in CELC. Creative Planning bought a new stake in shares of Celcuity in the 2nd quarter valued at about $177,000. Rhumbline Advisers raised its position in shares of Celcuity by 1.2% in the 2nd quarter. Rhumbline Advisers now owns 42,697 shares of the company’s stock valued at $570,000 after acquiring an additional 503 shares during the period. XTX Topco Ltd bought a new position in Celcuity during the 2nd quarter worth approximately $169,000. Quantinno Capital Management LP grew its holdings in Celcuity by 20.7% during the second quarter. Quantinno Capital Management LP now owns 243,042 shares of the company’s stock valued at $3,245,000 after purchasing an additional 41,756 shares during the period. Finally, Paloma Partners Management Co grew its holdings in Celcuity by 285.8% during the second quarter. Paloma Partners Management Co now owns 82,137 shares of the company’s stock valued at $1,097,000 after purchasing an additional 60,849 shares during the period. Institutional investors own 63.33% of the company’s stock.

Analyst Upgrades and Downgrades

CELC has been the topic of several analyst reports. Leerink Partners set a $155.00 target price on shares of Celcuity in a report on Tuesday, June 2nd. Craig Hallum reaffirmed a “buy” rating and set a $178.00 price objective on shares of Celcuity in a research note on Wednesday, July 15th. Guggenheim lifted their target price on Celcuity from $165.00 to $175.00 and gave the stock a “buy” rating in a report on Monday, August 17th. Citizens Jmp reissued a “market outperform” rating and issued a $177.00 target price on shares of Celcuity in a research note on Monday, August 17th. Finally, Needham & Company LLC lowered their price target on Celcuity from $157.00 to $140.00 and set a “buy” rating for the company in a report on Friday, August 14th. Ten research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $154.55.

Celcuity Stock Up 0.7%

NASDAQ:CELC opened at $89.06 on Tuesday. The stock has a 50-day simple moving average of $94.62 and a 200 day simple moving average of $107.04. Celcuity, Inc. has a 52-week low of $44.42 and a 52-week high of $151.02. The company has a market cap of $4.36 billion, a PE ratio of -20.71 and a beta of 0.21. The company has a debt-to-equity ratio of 6.04, a quick ratio of 8.93 and a current ratio of 8.93.

Celcuity (NASDAQ:CELC) last released its quarterly earnings results on Thursday, August 13th. The company reported ($1.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.28). On average, sell-side analysts expect that Celcuity, Inc. will post -4.75 EPS for the current fiscal year.

Celcuity Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.